VC
RAPP

VarCov Co’s Rapport Therapeutics RAPP Stock Holding History

VarCov Co’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Sell
12,895
-2,578
-17% -$94.8K 0.2% 174
2026
Q1 		$484K Buy
+15,473
New +$435K 0.18% 214

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

VarCov Co's RAPP Position: Q2 2026 in Review

VarCov Co reduced its Rapport Therapeutics (RAPP) stake by 17% in Q2 2026, selling an estimated $94.8K and leaving 12,895 shares worth $537K. The position accounts for 0.2% of the portfolio, ranked #174.

VarCov Co first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • VarCov Co held 12,895 shares of Rapport Therapeutics worth $537K as of Q2 2026.
  • VarCov Co sold 2,578 Rapport Therapeutics shares in Q2 2026, an estimated $94.8K.
  • Rapport Therapeutics made up 0.2% of VarCov Co's portfolio in Q2 2026, its #174 holding.
  • VarCov Co first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.